[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-gastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-gastric-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,69,99,127,155,186,209,232,251],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100641601","phase-2-hipec-priming-followed-by-serplulimab-plus-soxxelox-in-locally-advanced-gastric-cancer-100641601",false,"NCT07621484","HIPEC Priming Followed by Serplulimab Plus SOX\u002FXELOX in Locally Advanced Gastric Cancer","A Prospective Exploratory Study of a HIPEC Priming Strategy Followed by Serplulimab Combined With SOX\u002FXELOX as Neoadjuvant Therapy for Locally Advanced Gastric Cancer","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive); gender unrestricted.\n* Histologically confirmed gastric or gastroesophageal junction adenocarcinoma via endoscopic biopsy.\n* Clinical stage cT3-4a (imaging evidence of tumor invasion into or penetration through the serosa), any N (lymph node positive), M0 (no distant organ metastasis), based on the 8th Edition of the AJCC Staging Manual.\n* HER2-negative disease, defined as HER2 IHC 0 or 1+, or IHC 2+ with negative ISH.\n* Diagnostic laparoscopy confirms the absence of macroscopic peritoneal metastasis (P0) and negative peritoneal lavage cytology (CY0).\n* Adequate cardiac function, rendering the patient eligible for curative-intent resection. If clinically indicated, patients with underlying ischemic heart disease, valvular heart disease, or other severe cardiac conditions must undergo a preoperative cardiac evaluation by a cardiologist.\n* ECOG Performance Status (PS) score of 0 or 1 within 7 days prior to enrollment.\n* Anticipated survival time of ≥ 6 months.\n* Hepatitis B surface antigen (HBsAg) negative (-) and Hepatitis B core antibody (HBcAb) negative (-). If HBsAg is positive (+) or HBcAb is positive (+), the Hepatitis B virus DNA (HBV-DNA) level must be \\\u003C 1000 copies\u002FmL, \\\u003C 200 IU\u002FmL, or below the upper limit of normal (ULN) at the study center to be eligible for enrollment.\n* HCV antibody negative (-).\n* Major organ function is normal, defined as meeting the following criteria (having not received transfusions of blood products, albumin, recombinant human thrombopoietin, or colony-stimulating factors \\[CSF\\] within 14 days prior to randomization):\n\nHematologic System Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹\u002FL Platelets (PLT) ≥ 100×10⁹\u002FL Hemoglobin (Hb) ≥ 90 g\u002FL Liver Function Total Bilirubin (TBIL) ≤ 1.5×Upper Limit of Normal (ULN) Alanine Aminotransferase (ALT) ≤ 2.5×ULN; ≤ 5.0×ULN for patients with liver metastases Aspartate Aminotransferase (AST) ≤ 2.5×ULN; ≤ 5.0×ULN for patients with liver metastases Alkaline Phosphatase (ALP) ≤ 2.5×ULN; ≤ 5.0×ULN for patients with liver and\u002For bone metastases Albumin ≥ 25 g\u002FL Renal Function Creatinine Clearance (CrCl) ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula) Coagulation Function Activated Partial Thromboplastin Time (APTT) ≤ 1.5×ULN Prothrombin Time (PT) ≤ 1.5×ULN International Normalized Ratio (INR) ≤ 1.5×ULN -Female patients must meet the following criteria:\n\nBe in a postmenopausal state (defined as having had no menstruation for at least 1 year, with no other confirmed cause for amenorrhea other than menopause), or have undergone surgical sterilization (removal of ovaries and\u002For uterus); alternatively, patients with reproductive potential must simultaneously meet the following requirements:\n\n* A serum pregnancy test result must be negative within 7 days prior to randomization;\n* Agree to use a contraceptive method with an annual failure rate of \\\u003C 1% or practice abstinence (avoidance of heterosexual intercourse) (from the time of signing the informed consent form until at least 120 days after the last dose of the investigational drug, and at least 6 \\[months\\] after the last dose of the chemotherapy drug ...months (contraceptive methods with an annual failure rate of \\\u003C 1% include bilateral tubal ligation, vasectomy, correct use of ovulation-suppressing hormonal contraceptives, hormone-releasing intrauterine devices \\[IUDs\\], and copper-containing IUDs);\n* Must not be breastfeeding. -Male patients must meet the following criteria: Agree to practice abstinence (avoid heterosexual intercourse) or use contraception, as specified below: If the partner is a female of childbearing potential or is pregnant, the male patient must practice abstinence or correctly use condoms for contraception-to prevent drug exposure to the embryo-during the chemotherapy treatment period and for at least 6 months after the last dose of chemotherapy medication, and for at least 120 days after the last dose of the investigational drug. The reliability of sexual abstinence should be evaluated with reference to the duration of the clinical study, patient preference, and lifestyle. Periodic abstinence (e.g., calendar-based, ovulation-based, basal body temperature, or post-ovulation methods) and withdrawal (coitus interruptus) are not considered acceptable methods of contraception.\n\nExclusion Criteria:\n\n* History of other active malignancies within the past 5 years, or the presence of other active malignancies at the time of enrollment. Patients with cured localized tumors-such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, or carcinoma in situ of the breast-are eligible for enrollment.\n* Presence of documented distant metastases (e.g., liver, lung, or bone metastases) or laparoscopically confirmed peritoneal seeding (P1).\n* Patients scheduled to undergo, or with a history of having undergone, organ or bone marrow transplantation.\n* Occurrence of myocardial infarction or poorly controlled arrhythmias (including a QTc interval ≥ 450 ms for males or ≥ 470 ms for females; QTc interval calculated using the Fridericia formula) within 6 months prior to enrollment.\n* Presence of NYHA Class III or IV heart failure, or a cardiac ultrasound result showing a Left Ventricular Ejection Fraction (LVEF) \\\u003C 50%.\n* Human Immunodeficiency Virus (HIV) infection.\n* Presence of active pulmonary tuberculosis.\n* History of, or current presence of, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or severe impairment of pulmonary function that could interfere with the detection or management of suspected drug-related pulmonary toxicity.\n* Presence of a known active or suspected autoimmune disease. Exceptions are made for patients whose disease is in a stable state at the time of enrollment (defined as requiring no systemic immunosuppressive therapy).\n* Receipt of a live vaccine within 28 days prior to enrollment; inactivated viral vaccines for seasonal influenza are permitted.\n* Patients requiring systemic corticosteroid therapy (at a prednisone-equivalent dose \\> 10 mg\u002Fday) or other immunosuppressive medications within 14 days prior to enrollment or during the study period. However, the following exceptions are permitted: in the absence of active autoimmune disease, patients may use topical or inhaled corticosteroids, or receive adrenal replacement therapy at a prednisone-equivalent dose ≤ 10 mg\u002Fday.\n* Presence of any active infection requiring systemic anti-infective treatment within 14 days prior to enrollment; prophylactic antibiotic treatment (e.g., for the prevention of urinary tract infections or chronic obstructive pulmonary disease) is an exception.\n* Prior receipt of any anti-tumor therapy for the current gastric cancer, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy.\n* Currently receiving treatment in another clinical study, or the planned start date of the treatment in this study is less than 14 days after the completion of treatment in a previous clinical study.\n* Known history of severe allergy to any monoclonal antibody or excipients of the investigational drug.\n* Known history of substance abuse (including drug abuse); patients who have ceased alcohol consumption are eligible for enrollment.\n* Presence of any condition that may increase the risks associated with study participation or the investigational drug, or presence of other severe, acute, or chronic diseases that, in the investigator's judgment, render the patient unsuitable for participation in the clinical study.","ALL","18 Years","75 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Patients with locally advanced gastric cancer (LAGC), particularly those with serosal invasion, remain at high risk of peritoneal recurrence despite standard perioperative treatment. Hyperthermic intraperitoneal chemotherapy (HIPEC) may eradicate free intraperitoneal tumor cells and microscopic peritoneal disease while potentially enhancing systemic anti-tumor immune activation.\n\nThis is a prospective, single-center, single-arm exploratory study evaluating a HIPEC priming strategy followed by serplulimab-based neoadjuvant therapy in patients with locally advanced gastric cancer (cT3-4aN+M0). Eligible patients will undergo diagnostic laparoscopy confirming no visible peritoneal metastasis (P0) and negative peritoneal cytology (CY0), followed by docetaxel-based HIPEC.\n\nAfter recovery from HIPEC, patients will initially receive one cycle of serplulimab combined with fluoropyrimidine monotherapy (S-1 or capecitabine), followed by subsequent cycles of serplulimab combined with SOX\u002FXELOX chemotherapy prior to radical gastrectomy.\n\nThe primary endpoints are pathological complete response (pCR) rate and major pathological response (MPR) rate. Secondary endpoints include R0 resection rate, objective response rate (ORR), peritoneal recurrence-free survival (PRFS), overall survival (OS), and safety.",[27,28,29],"Locally Advanced Gastric Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[27,31,32,33],"HIPEC","Hyperthermic Intraperitoneal Chemotherapy","Peritoneal Recurrence","NOT_YET_RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":21},"2026-07-01",{"date":42,"type":21},"2028-05-09",{"name":44,"class":45},"Shanghai Changzheng Hospital","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100643638","phase-2-ipilimumab-n01-plus-sintilimab-and-modified-xelox-as-conversion-therapy-in-unresectable-locally-advanced-gastric-cancer-100643638","NCT07638631","Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer","A Single-Arm, Prospective, Multicenter Study of Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer","DIAMC-GC","Inclusion Criteria:\n\n1. Provided written informed consent before performing any trial-related procedures;\n2. Age ≥18 years old and ≤80 years old, regardless of gender;\n3. Histologically confirmed gastric or gastroesophageal junction adenocarcinoma, PDL1 CPS≥1, and unresectable locally advanced gastric cancer confirmed by MDT or investigator assessment (based on imaging and EUS assessment). Conclusions: The main reasons for unresectable locally advanced gastric cancer at initial diagnosis include: severe invasion of the primary tumor, inability to separate from surrounding organs or wrap around important blood vessels, or metastasis and fixation of regional lymph nodes, and inability to achieve R0 resection according to MDT discussion or investigator evaluation. R0 resection was considered unresectable if a Whipple's operation was performed in conjunction with it.\n4. At least one radiographic measurable lesion according to response evaluation Criteria in Solid Tumors (RECIST, version 1.1);\n5. No previous gastric cancer surgery, anti-tumor chemoradiotherapy\u002Fimmunotherapy;\n6. ECOG score 0-1;\n7. Expected survival time \\> 6 months;\n8. Adequate organ function, subject must meet the following laboratory indicators:\n\n1\\) absolute neutrophil count (ANC) ≥1.5x109\u002FL without using granulocyte colony-stimulating factor for the past 14 days.\n\n2\\) platelet count ≥75×109\u002FL without blood transfusion in the past 14 days. 3) hemoglobin ≥75g\u002FL without blood transfusion or erythropoietin use in the past 14 days; 4) Total bilirubin ≤3× upper limit of normal value (ULN); 5) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; 6) serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥50 ml\u002Fmin (exclusion due to height); 7) good coagulation function, defined as INR or PT ≤1.5 times ULN; 8) Euthyroid, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH was beyond the normal range, the subjects could be included if the total T3 (or FT3) and FT4 were within the normal range.\n\n9\\. Myocardial enzymes within the normal range (simple laboratory abnormalities without clinical significance judged by the investigators were also allowed to be enrolled); 10. For women of childbearing age, a negative urine or serum pregnancy test should be performed within 3 days before receiving the first dose of study drug (day 1 of cycle 1). If a urine pregnancy test result could not be confirmed as negative, a blood pregnancy test was requested. Women who were not of reproductive age were defined as those who had been postmenopausal for at least 1 year or had undergone surgical sterilization or hysterectomy.\n\n11\\. If there was a risk of pregnancy, all subjects (male or female) were required to use contraception with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last dose of study drug on treatment (or 180 days after the last dose of chemotherapy drug).\n\nExclusion Criteria:\n\n1. Known HER2 positivity;\n2. Malignant diseases other than gastric cancer (excluding radical skin basal cell carcinoma, skin squamous cell carcinoma, and\u002For radical resection in situ carcinoma) diagnosed within 5 years before the first dose;\n3. Are currently participating in an interventional clinical study treatment, or have received another study drug or investigational device within 4 weeks before the first dose;\n4. Previous therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent targeting another T-cell receptor that stimulates or coinhibits it (e.g., CTLA-4, OX-40, CD137);\n5. Active autoimmune disease leading to systemic therapy (e.g., disease-modifying agents, glucocorticoids, or immunosuppressive agents) occurred within 1 year before the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency) were not considered systemic therapy;\n6. Receiving systemic glucocorticoids (excluding topical glucocorticoids by nasal spray, inhalation, or other route) or any other form of immunosuppressive therapy within 7 days before the first study dose; Note: Physiologic doses of glucocorticoids (≤10 mg per day of prednisone or equivalent) were allowed.\n7. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;\n8. Patients with known allergy to sintilimab, ipilimumab injection N01, chemotherapy active ingredients or excipients;\n9. Has not fully recovered from any intervention-related toxicity and\u002For complications before starting treatment (i.e., grade ≤1 or baseline, excluding fatigue or alopecia);\n10. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1\u002F2 antibody positive);\n11. Known signs of active bleeding on endoscopy and a history of gastrointestinal perforation and\u002For fistula within 6 months;\n12. Received anti-tumor Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local use to control ascites) with systemic treatment within 2 weeks before the first dose;\n13. Uncontrolled active hepatitis B (defined as both HBsAg positivity and HBV-DNA copies greater than the upper limit of normal range in the laboratory of the research center);\n\nNote: Subjects with hepatitis B who met the following criteria were also eligible for inclusion:\n\n1. HBV viral load \\&lt before the first administration; 1000 copies \u002Fml (200 IU\u002Fml), subjects should receive anti-HBV therapy throughout the study drug treatment to avoid viral reactivation\n2. For subjects with anti-HBc (+), HBsAg (-), anti-hbs (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but viral reactivation should be closely monitored 14. Active HCV-infected subjects (HCV-antibody positive and HCV-RNA level above the lower limit of detection); 15. Received a live vaccine within 30 days before the first dose (cycle 1, day 1); Note: Administration of injectable inactivated virus vaccine against seasonal influenza within 30 days before the first dose is allowed; Live, attenuated, intranasal influenza vaccine was not allowed.\n\n16\\. Pregnant or lactating women; 17. The presence of any serious or uncontrolled systemic illness, such as:\n\n1. significant rhythm, conduction or morphological abnormalities in resting ECG, such as complete left bundle branch block, ≥ Ⅱ degree heart block, ventricular arrhythmia or atrial fibrillation;\n2. unstable angina, congestive heart failure, New York Heart Association (NYHA) grade ≥ 2 chronic heart failure;\n3. any arterial thrombosis, embolism, or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, etc. within 6 months before enrollment;\n4. poor blood pressure control (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg);\n5. patients had a history of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose of glucocorticoid, or current clinically active interstitial lung disease;\n6. active pulmonary tuberculosis;\n7. presence of active or uncontrolled infection requiring systemic therapy;\n8. presence of clinically active diverticulitis, abdominal abscess, or gastrointestinal obstruction;\n9. liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;\n10. poorly controlled diabetes (fasting blood glucose (FBG) \\> 10mmol\u002FL);\n11. Urine routine test showed urinary protein ≥++ and confirmed 24-hour urinary protein quantitation \\> 2.0 g;\n12. those with mental disorders who are unable to cooperate with treatment; 18. Medical history or evidence of disease, abnormal treatment or laboratory test results, or other conditions deemed by the investigator to be inappropriate for enrollment, or other potential risks considered by the investigator to be inappropriate for participation in the study that may interfere with the trial results or prevent the participant from participating in the study.","80 Years",{"count":56,"type":21},30,[24],"This study was a prospective, single-arm, multi-center, phase Ⅱ clinical study to investigate the efficacy and safety of ipilimumab injection N01 combined with sintilimab and modified XELOX conversion therapy in patients with unresectable locally advanced gastric cancer who had not received systemic treatment.",[27],"2026-06-04",{"date":62,"type":38},"2026-06-10",{"date":35,"type":21},{"date":65,"type":21},"2030-06-15",{"name":67,"class":68},"Chen Lizhu","OTHER_GOV",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100637792","pulsar-combined-with-immunotherapy-for-unresectable-locally-advanced-gastric-cancer-100637792","NCT07607119","PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer","A Prospective Phase II Study of Systemic Therapy With Immunotherapy Combined With Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Unresectable Locally Advanced Gastric Cancer","Inclusion Criteria:\n\nAge 19 or more years. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed gastric adenocarcinoma. Tumor biomarker status: HER-2 negative, EBV negative, and Microsatellite Stable (MSS).\n\nUnresectable, locally advanced extent at initial staging (Para-aortic lymph node \\[PALN\\] and Supraclavicular lymph node \\[SCN\\] metastases are allowed).\n\nHas completed 3 or more cycles of first-line systemic therapy combined with immunotherapy without evidence of disease progression.\n\nPresence of at least one evaluable lesion according to RECIST v1.1 that is deemed safely irradiable by the investigator.\n\nVoluntary written informed consent provided by the subject.\n\nExclusion Criteria:\n\nPregnant or lactating women. Presence of brain metastases or leptomeningeal involvement. Prior history of radiation therapy to the intended target site. Severe uncontrolled comorbidities that, in the investigator's opinion, limit study participation or treatment compliance (e.g., uncontrolled infection, heart failure, arrhythmia, psychiatric illness).\n\nInability or unwillingness to comply with the study protocol procedures. Any condition deemed inappropriate for study participation by the principal investigator or attending physician.","19 Years",{"count":78,"type":21},53,[80],"NA","The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.",[28,83,27,84],"Stomach Neoplasms","Unresectable Gastric Cancer",[86,87],"HER2-negative Stomach Cancer","Microsatellite Stable Gastric Cancer","RECRUITING","2026-05-24",{"date":91,"type":38},"2026-05-28",{"date":93,"type":38},"2026-05-15",{"date":95,"type":21},"2030-04-30",{"name":97,"class":45},"Samsung Medical Center",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100623789","multimodal-ai-for-predicting-response-to-neoadjuvant-immunotherapy-in-gastric-cancer-prism-gc-100623789","NCT07401199","Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","A Prospective, Multicenter, Real-World Cohort Study for the Development and Validation of a Multimodal Artificial Intelligence System to Predict Response to Neoadjuvant Chemo-Immunotherapy in Locally Advanced Gastric Cancer (The PRISM-GC Study)","Inclusion Criteria:\n\nAge ≥ 18 years.\n\nHistologically confirmed gastric or gastroesophageal junction adenocarcinoma.\n\nClinical stage cT3-4a, N+, M0 (locally advanced) assessed by CT\u002FMRI and endoscopic ultrasound.\n\nScheduled to receive neoadjuvant chemotherapy combined with PD-1 inhibitors (regimens including but not limited to SOX\u002FXELOX + Sintilimab\u002FTislelizumab\u002FCamrelizumab, etc.) as standard of care.\n\nAvailability of standard pre-treatment contrast-enhanced abdominal CT images.\n\nWillingness to provide peripheral blood samples and tumor tissue (biopsy\u002Fsurgical) for sequencing and analysis.\n\nECOG performance status 0-1.\n\nAdequate organ function to tolerate systemic chemotherapy.\n\nExclusion Criteria:\n\nEvidence of distant metastasis (Stage IV) or unresectable disease.\n\nPrevious systemic anti-tumor therapy for gastric cancer (chemotherapy, radiotherapy, or immunotherapy).\n\nHistory of other malignancies within the past 5 years.\n\nActive autoimmune diseases requiring systemic immunosuppressive treatment (contraindication for PD-1 inhibitors).\n\nEmergency surgery due to obstruction, perforation, or uncontrolled bleeding.\n\nSevere metallic artifacts on CT images that interfere with radiomic feature extraction.\n\nPregnancy or lactation.",{"count":107,"type":21},2000,"OBSERVATIONAL","Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy. While this approach is effective for many patients, responses vary significantly, and there are currently no reliable tools to predict which patients will benefit the most before treatment begins.\n\nThe PRISM-GC study aims to develop and validate a novel Artificial Intelligence (AI) system to address this need. This is a prospective, observational study that will collect data from patients diagnosed with locally advanced gastric cancer who are scheduled to receive standard neoadjuvant chemotherapy combined with immunotherapy in a real-world clinical setting. The specific choice of immunotherapy drug is determined by the treating physician and is not dictated by the study.\n\nResearchers will analyze standard preoperative CT scans and pathological tissue slides using advanced deep learning algorithms. The goal is to create a \"multimodal\" AI model that can accurately predict how well a tumor will respond to treatment (specifically, whether the tumor will disappear or shrink significantly). If successful, this AI tool could help doctors personalize treatment plans in the future, ensuring that each patient receives the most effective therapy while avoiding unnecessary side effects.",[111,27],"Gastric Cancer (GC)",[113,114,115,116,117],"Neoadjuvant Immunotherapy","Artificial Intelligence","Deep Learning","Pathological Complete Response","PD-1 Inhibitors","2026-05-13",{"date":93,"type":38},{"date":121,"type":38},"2026-02-05",{"date":123,"type":21},"2027-12-30",{"name":125,"class":45},"Qun Zhao",9,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":98},"100561981","proximal-gastrectomy-vs-total-gastrectomy-in-locally-advanced-upper-gastric-cancer-after-neoadjuvant-therapy-100561981","NCT06597227","Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy","Comparison of Clinical Efficacy of Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After SOX Combined With Anti-PD-1 Neoadjuvant Therapy：a Prospective, Multi-center, Randomised，Controlled Trial","TJHGC01","Inclusion Criteria:\n\n* To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and\u002For cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT\u002FMRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy\u002Fimmunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  \u003C!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g\u002FL; Absolute neutrophil count (ANC) ≥1.5×109\u002FL; Platelet (PLT) ≥80×109\u002FL;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL\u002Fmin;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects.\n\nExclusion Criteria:\n\n* To be eligible to participate in this study, all patients must meet all the following criteria:\n\n  1. The subjects voluntarily joined the study and were able to sign the informed consent with good compliance;\n  2. Age 18-75 years old (at the time of signing the informed consent), both male and female;\n  3. Histologically and\u002For cytologically confirmed upper gastric carcinoma (adenocarcinoma), locally advanced according to AJCC Edition 8 criteria, cT3-4 or N+M0 according to endoscopic ultrasound or enhanced CT\u002FMRI scanning (combined with diagnostic laparoscopic exploration if necessary) , and consent to neoadjuvant therapy. Investigators assessed the lesion as resectable or potentially resectable;\n  4. Have not received systematic treatment for the current disease, including anti-tumor chemoradiotherapy\u002Fimmunotherapy;\n  5. ECOG score 0-1;\n  6. Expected survival ≥6 months;\n  7. Preoperative chest, abdominal, pelvic CT or PET-CT to exclude distant metastasis;\n  8. The major organs function well and meet the following criteria:\n\n  \u003C!-- -->\n\n  1. Blood routine examination (no blood transfusion within 14 days, no hematopoietic stimulating drugs to correct the state) : hemoglobin (Hb) ≥90g\u002FL; Absolute neutrophil count (ANC) ≥1.5×109\u002FL; Platelet (PLT) ≥80×109\u002FL;\n  2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Serum total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60mL\u002Fmin;\n  3. Coagulation function: activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n  4. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥50%;\n  5. Assessed with adequate organ function by doctors. 9. Fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study, have a negative serological pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects.",{"count":136,"type":21},404,[80],"We plan to evaluate the efficacy and safety of proximal gastric vs. total gastric radical resection after SOX combined with anti-PD-1 neoadjuvant therapy in locally advanced upper gastric cancer",[27],[141,142,143,144,145],"Locally advanced gastric cancer","neoadjuvant chemotherapy","immunotherapy","Proximal radical gastrectomy","total radical gastrectomy","2026-04-22",{"date":148,"type":38},"2026-04-27",{"date":150,"type":38},"2024-03-01",{"date":152,"type":21},"2028-12-30",{"name":154,"class":45},"Guihua Wang",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":163,"targetDuration":165,"studyType":108,"phases":4,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":98},"100583800","the-safety-and-efficacy-of-robotic-assisted-surgery-using-vessel-sealer-extend-in-locally-advanced-gastric-cancer-100583800","NCT06881043","The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer","A Multicenter, Prospective, Observational Cohort Study to Assess the Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer (STARS-GC09)","STARS-GC09","Inclusion Criteria:\n\n* Age from over 18 to under 75 years\n* Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy\n* cT2-4a, N-\u002F+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition\n* Preoperative abdominal enhanced CT and lung CT (or PET-CT) showed no distant metastasis\n* Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale\n* ASA (American Society of Anesthesiology) class I to III\n* Written informed consent\n\nExclusion Criteria:\n\n* Gastric multiple primary carcinoma or multiple primary cancer\n* History of previous upper abdominal surgery (except laparoscopic cholecystectomy)\n* History of previous gastric surgery (except ESD\u002FEMR (Endoscopic Submucosal Dissection\u002FEndoscopic Mucosal Resection ) for gastric cancer)\n* Preoperative gastric CT evaluation and chest and abdominal imaging evaluation were not performed before surgery, and the clinical stage of the tumor was not comprehensively evaluated\n* Enlarged or bulky regional lymph node （diameter over 3cm）supported by preoperative imaging\n* History of other malignant disease within the past 5 years\n* History of previous neoadjuvant chemotherapy or radiotherapy\n* History of unstable angina or myocardial infarction within the past 6 months\n* History of cerebrovascular accident within the past 6 months\n* History of continuous systematic administration of corticosteroids within 1 month\n* FEV1\\\u003C50% of the predicted values\n* Women during pregnancy or breast-feeding\n* Severe mental disorder\n* Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer\n* Preoperative evaluation requires combined organ resection\n* Requirement of simultaneous surgery for other disease",{"count":164,"type":21},300,"3 Years","Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer-related deaths. Surgical resection is the primary treatment, with laparoscopic-assisted gastrectomy (LG) being a minimally invasive option. However, LG is limited by restricted instrument mobility and hand tremors, which affect precision. The Da Vinci robotic system enhances surgical precision with 3D magnification, improved hand-eye coordination, tremor filtration, and flexible instruments. It is especially beneficial in complex procedures like D2 lymph node dissection and lower mediastinal lymph node clearance. Unlike laparoscopic surgery, robotic surgery offers superior flexibility and reduced pancreatic injury during dissection. Robotic-assisted gastrectomy (RG) offers advantages over LG, such as reduced blood loss, shorter hospital stays, and improved lymph node dissection. However, its short-term benefits remain debated, and most studies focus on early gastric cancer. The safety and efficacy of RG for advanced gastric cancer are not well-established.\n\nVascular coagulation is crucial in minimally invasive surgery. Ultrasonic devices, though widely used, can cause thermal damage due to high temperatures. In contrast, the Vessel Sealer Extend (VSE) offers greater flexibility and precision. It allows 540° instrument rotation, coagulates vessels up to 7 mm in diameter with lower energy, and minimizes thermal injury. Retrospective studies show RG with VSE may have faster recovery and fewer complications than LG. However, further prospective, multicenter studies are needed to confirm these benefits for advanced gastric cancer.\n\nThe investigators propose a multicenter, observational study to evaluate RG with VSE in advanced gastric cancer, assessing safety, recovery, and oncological outcomes.",[27,28],[169,170,171,172,173,174,175,176],"Robot-assisted surgery","Vessel sealer extend","Gastrectomy","Laparoscopic-assisted surgery","Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms","Gastrointestinal Diseases","2025-03-11",{"date":179,"type":38},"2025-03-18",{"date":181,"type":38},"2024-11-20",{"date":183,"type":21},"2029-12-01",{"name":185,"class":45},"The First Hospital of Jilin University",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100551425","phase-2-efficacy-and-safety-of-neoadjuvant-sintilimab-plus-flot-versus-sintilimab-plus-sox-phase-ii-clinical-trial-for-patients-with-locally-advanced-gastric-cancer-100551425","NCT06459921","Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer","Efficacy and Safety of Neoadjuvant Sintilimab Puls FLOT Versus Sintilimab Puls SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer","Inclusion Criteria:\n\n* 1\\. Age \\>=18 years and \\\u003C100 years.\n* 2\\. Diagnosed with locally advanced gastric cancer.\n* 3\\. Eastern Cooperative Oncology Group ECOG PS score 0-1.\n* 4\\. adoption of preoperative chemotherapy treatment and PD-1 antibody therapy.\n* 5\\. deficient mismatch repair identified by pathological detection.\n\nExclusion Criteria:\n\n* 1\\. Locally advanced unable to resect or metastatic tumors.\n* 2\\. Patients with recurrence of residual gastric cancer\n* 3\\. Patients refusing surgical resection after preoperative chemotherapy therapy.\n* 4\\. Have received any anti-tumor therapy such as chemotherapy, radiotherapy, immunotherapy, etc., or have been more than 180 days since the last treatment.\n* 5\\. Patients with confirmed allergy to the study drug and\u002For its excipients.\n* 6\\. Severe malnutrition and active autoimmune diseases.\n* 7\\. Pregnant or lactating women.\n* 8\\. Patients with medical systemic diseases and psychiatric diseases that are not amenable to chemotherapy.\n* 9\\. Patients with acute infections requiring antibiotic treatment.\n* 10\\. Patients with acute infections requiring antibiotic treatment.\n* 11\\. Patients who are concomitantly receiving other immunotherapy, corticosteroids, and other anticancer therapies during the trial.\n* 12\\. Positive test result for hepatitis B or hepatitis C virus.\n* 13\\. Untreated central nervous system metastatic peripheral neuropathy (\\>grade 1).\n* 14\\. History of malignancy within the past 5 years (with the exception of curative, localized cancer).\n* 15\\. Patients who are not expected to achieve R0 resection.\n* 16\\. Weight loss greater than or equal to 20% within 4 weeks before the first dose.\n* 17\\. Patients with multiple factors affecting oral medication.\n* 18\\. Vaccination within 4 weeks prior to the first dose of study drug.\n* 19\\. Patients who have received immune checkpoint inhibitors and develop serious adverse reactions after treatment and need to be permanently disabled.\n* 20\\. The investigator believes that the subject has other serious systemic diseases or other reasons and is not suitable for this clinical study.",{"count":194,"type":21},200,[24],"This study aims to investigate the efficacy and safety of Sintilimab combined with FOLT versus Sintilimab combined with SOX in patients with locally advanced gastric cancer. The research design is intended to observe the comparison of conversion therapy effects, disease-free survival, R0 resection rate, and safety evaluation between the two groups.",[198,199,27],"Neoadjuvant Chemotherapy","Sintilimab","2024-10-09",{"date":202,"type":38},"2024-10-10",{"date":204,"type":21},"2024-12-01",{"date":206,"type":21},"2028-12-31",{"name":208,"class":45},"Xijing Hospital",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100486150","phase-3-clinical-efficacy-in-neoadjuvant-treatment-of-locally-advanced-gastric-cancer-with-different-immunotypes-100486150","NCT05610332","Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes","Clinical Efficacy of Albumin Paclitaxel Plus Carrelizumab Versus FLOT in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes--A Multi-center, Randomised, Open, Phase 3 Clinical Trial","Inclusion Criteria:\n\n1\\. Age from 18 to 75 years, all sex； 2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by histology or cytology； 3. CT\u002FMRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of gastric cancer staging as cT2-4a and\u002For N+ and M0 before operation.； 4. Measurable lesions at least should be detected by CT\u002FMRI examination in accordance with the RECIST1.1.（CT scan of tumor lesion length≥10mm，CT scan short diameter of lymph node≥15mm，scan slice thickness 5mm）; 5. ECOG(Eastern Cooperative Oncology Group) PS(Performance Status):0-1 scores; 6. The expected survival time is more than 12 weeks; 7. The main organ function is normal, which should meet the following criteria:\n\n1. blood routine examination standards should be met（no blood transfusion within 14 days）\n\n   1. HB≥100g\u002FL，\n   2. WBC≥3×109\u002FL\n   3. ANC≥1.5×109\u002FL，\n   4. PLT≥100×109\u002FL；\n2. biochemical examination shall comply with the following criteria：\n\n   1. BIL \\\u003C1.5normal upper limit（ULN），\n   2. ALT和AST\\\u003C2.5ULN，GPT≤1.5×ULN；\n   3. serum Cr≤1ULN，creatinine clearance rate\\>60ml\u002Fmin（Cockcroft-Gault formula） 8. women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug.； 9. No other clinical studies were conducted before and during the treatment； participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy\n2. Patients with contraindications for surgical treatment and chemotherapy or whose physical condition and organ function do not allow for major abdominal surgery；\n3. Patients with metastasis；\n4. Having any active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Patients with vitiligo or cured childhood asthma\u002Fallergies who did not need any intervention in adulthood were excluded; Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone; Type 1 diabetes with stable doses of insulin；\n5. A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation；\n6. Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease; Jaundice or obstruction of the digestive tract with severe infection；\n7. Pregnant or lactating women；\n8. The blood pressure of patients with hypertension cannot be reduced to the normal range by the antihypertensive drugs (systolic pressure \\>140 mmHg, diastolic pressure \\>90 mmHg)；\n9. With Ⅰ magnitude of coronary heart disease, arrhythmia (including QTc protracted between male \\> 450 ms, women \\> 470 ms) and cardiac insufficiency；\n10. Patients have a clear tendency with gastrointestinal bleeding, including the following situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena and hematemesis history in 2 months; and patients with fecal occult blood (+) and coagulation dysfunction (INR(international normalized ratio)\\>1.5, APTT(activated partial thromboplastin time)\\>1.5 ULN), with bleeding tendency;；\n11. Subjects have failed to control good cardiovascular clinical symptoms or disease, including but not limited to: such as: (1) the NYHA class II heart failure or above (2) unstable angina pectoris (3) MI occurred within 1 year (4) have clinical significance of supraventricular or ventricular arrhythmias without clinical intervention on or after clinical intervention is still poorly controlled；\n12. History of interstitial lung disease (except radiation pneumonia without hormone therapy), and history of non-infectious pneumonia；\n13. Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative \\>1.0g)；\n14. A person who has previously been allergic to any component of the drug in this study； The researchers consider those who were not suitable for inclusion.",{"count":217,"type":21},216,[219],"PHASE3","To evaluate the clinical efficacy of albumin paclitaxel combined with carelizumab and FLOT in the neoadjuvant treatment of locally advanced gastric cancer with different immune types",[27],"2022-11-08",{"date":224,"type":38},"2022-11-09",{"date":226,"type":21},"2022-11-01",{"date":228,"type":21},"2027-11-01",{"name":230,"class":45},"Fujian Medical University",2,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":248,"leadSponsor":250,"locationsCount":98},"100479591","phase-2-clinical-study-of-camrelizumab-apatinib-mesylate-and-nab-paclitaxel-combined-with-oxplatin-and-s-1-in-the-neoadjuvant-treatment-of-locally-advanced-gastric-cancer-with-different-genotypes-100479591","NCT05524974","Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes","Clinical Efficacy of Carrelizumab, Apatinib Mesylate, Albumin Paclitaxel Combined With Oxaliplatin and S-1 in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes--A Prospective, Multi-center, Randomized Controlled Study","Inclusion Criteria:\n\n1. Age from 18 to 75 years, all sex；\n2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by histology or cytology；\n3. CT\u002FMRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of gastric cancer staging as cT2-4a and\u002For N+ and M0 before operation.；\n4. measurable lesions at least should be detected by CT\u002FMRI examination in accordance with the RECIST1.1.（CT scan of tumor lesion length≥10mm，CT scan short diameter of lymph node≥15mm，scan slice thickness 5mm）;\n5. ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-1 scores;\n6. the expected survival time is more than 12 weeks;\n7. the main organ function is normal, which should meet the following criteria: （1）(1)blood routine examination standards should be met（no blood transfusion within 14 days）\n\n   1. HB≥100g\u002FL，\n   2. WBC≥3×109\u002FL\n   3. ANC≥1.5×109\u002FL，\n   4. PLT≥100×109\u002FL； （2）biochemical examination shall comply with the following criteria：\n\n   \u003C!-- -->\n\n   1. BIL \\\u003C1.5normal upper limit（ULN），\n   2. ALT和AST\\\u003C2.5ULN，GPT≤1.5×ULN；\n   3. serum Cr≤1ULN，creatinine clearance rate\\>60ml\u002Fmin（Cockcroft-Gault formula）\n8. women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug.；\n9. No other clinical studies were conducted before and during the treatment； participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy\n2. Patients with contraindications for surgical treatment and chemotherapy or whose physical condition and organ function do not allow for major abdominal surgery；\n3. patients with metastasis；\n4. Having any active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Patients with vitiligo or cured childhood asthma\u002Fallergies who did not need any intervention in adulthood were excluded; Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone; Type 1 diabetes with stable doses of insulin；\n5. A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation；\n6. Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease; Jaundice or obstruction of the digestive tract with severe infection；\n7. pregnant or lactating women；\n8. The blood pressure of patients with hypertension cannot be reduced to the normal range by the antihypertensive drugs (systolic pressure \\>140 mmHg, diastolic pressure \\>90 mmHg)；\n9. With Ⅰ magnitude of coronary heart disease, arrhythmia (including QTc protracted between male \\> 450 ms, women \\> 470 ms) and cardiac insufficiency；\n10. Patients have a clear tendency with gastrointestinal bleeding, including the following situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena and hematemesis history in 2 months; and patients with fecal occult blood (+) and coagulation dysfunction (INR(international normalized ratio)\\>1.5, APTT(activated partial thromboplastin time)\\>1.5 ULN), with bleeding tendency;；\n11. Subjects have failed to control good cardiovascular clinical symptoms or disease, including but not limited to: such as: (1) the NYHA class II heart failure or above (2) unstable angina pectoris (3) MI occurred within 1 year (4) have clinical significance of supraventricular or ventricular arrhythmias without clinical intervention on or after clinical intervention is still poorly controlled；\n12. History of interstitial lung disease (except radiation pneumonia without hormone therapy), and history of non-infectious pneumonia；\n13. Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative \\>1.0g)；\n14. A person who has previously been allergic to any component of the drug in this study； The researchers consider those who were not suitable for inclusion.",{"count":240,"type":21},203,[24],"To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes",[27],"2022-08-30",{"date":246,"type":38},"2022-09-01",{"date":246,"type":21},{"date":249,"type":21},"2027-09-01",{"name":230,"class":45},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":98},"100359538","phase-3-standard-versus-super-extended-lymphadenectomy-after-neo-adjuvant-chemotherapy-for-gastric-cancer-100359538","NCT03961373","Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer","Neo-D2plus","Inclusion Criteria:\n\n* Age equal or greater than 18 years\n* IIA-IIIC histologically proven primary gastric adenocarcinoma, before the treatment with NAC. Not including gastro-oesophageal junction\u002Fcardia carcinoma but only Siewert 3, without any previous treatment (surgery and \u002F or chemotherapy) for this diagnosis\n* Lack in CT scan of following:\n\n  1. Mediastinal lymph nodes\n  2. Lung metastases\n  3. Peritoneal metastases\n  4. Liver metastases\n  5. Pleural effusion, ascites\n  6. Metastases to para-aortic lymph nodes No 16a2\u002Fb1\n  7. Metastases to lymph nodes located in the \"posterior\" area (8p, 12 b\u002Fp, 13)\n  8. Extra-regional lymph node metastases\n* ECOG performance status ≤ 2\n* No prior radio- or chemotherapy conflicting with the treatment of gastric cancer\n* No oesophageal invasion, or invasion \\\u003C=3cm\n* Negative peritoneal washing cytology findings and no peritoneal metastases in staging laparoscopy\n* No gastric stump cancer\n* No signs of cervical and subclavear lymph nodes or distal metastases\n* Patient's consent form obtained, signed and dated before beginning specific protocol procedures\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial\n\nExclusion Criteria:\n\n* Contraindications for any sort of appropriate chemotherapy according to local standards\n* Linitis plastica\n* Second uncontrolled malignant tumour (synchronous or metachronous (last 5 years) other than Cis or mucosal cancer\n* Neoplasms involving the esophago-gastric junction (Siewert types I and II)\n* Expected unresectability after neo-adjuvant treatment or progression in metastases\n* Emergency surgery due to bleeding or perforation\n* Uncontrolled infections\n* Other serious underlying medical conditions that could impair the ability of the patient to participate in the study\n* Pregnant or lactating women\n* Significant neurologic or psychiatric disorders\n* Severe cardiac illness (NYHA class IV)\n* Under treatment of systemic steroids\n* Participation in any other clinical trial that might interfere with the results of this trial\n* Lack of compliance\n* Inability to fill in questionnaires (insufficient command of language, dementia, lack of time)",{"count":259,"type":21},539,[219],"In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.",[27],"2019-05-21",{"date":265,"type":38},"2019-05-23",{"date":267,"type":38},"2018-11-05",{"date":269,"type":21},"2028-11-01",{"name":271,"class":45},"University of Siena"]